Clearmind Medicine (CMND) Short Interest Ratio & Short Volume

Short interest is the volume of Clearmind Medicine shares that have been sold short but have not yet been covered or closed out. As of June 30th, investors have sold 123,800 shares of CMND short. 4.17% of Clearmind Medicine's shares are currently sold short. Learn More on Clearmind Medicine's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 4.17% of Clearmind Medicine's floating shares are currently sold short.

Clearmind Medicine saw a decline in short interest in June. As of June 30th, there was short interest totaling 123,800 shares, a decline of 0.9% from the previous total of 124,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Clearmind Medicine currently has issued a total of 4,270,000 shares. Some of Clearmind Medicine's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Clearmind Medicine currently has a public float of 2,970,000 shares.

4.17% of Clearmind Medicine's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Clearmind Medicine: Allarity Therapeutics, Inc. (7.54%), Mannatech, Incorporated (0.58%), Athira Pharma, Inc. (3.94%), Flora Growth Corp. (1.57%), Edesa Biotech, Inc. (0.47%), Lexaria Bioscience Corp. (2.88%), HOOKIPA Pharma Inc. (1.58%), Synlogic, Inc. (0.53%), Ernexa Therapeutics Inc. (1.33%), Synaptogenix, Inc. (12.63%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($72.10 billion), Invesco QQQ ($26.89 billion), iShares Russell 2000 ETF ($19.61 billion), MicroStrategy Incorporated ($9.52 billion), iShares 20+ Year Treasury Bond ETF ($8.70 billion), WD-40 Company ($7.66 billion), Technology Select Sector SPDR Fund ($6.10 billion), Invesco S&P 500 Equal Weight ETF ($5.80 billion), Invesco S&P 500 Top 50 ETF ($5.53 billion), and Vanguard Large-Cap ETF ($5.35 billion). View all of the most shorted stocks.

Short selling CMND is an investing strategy that aims to generate trading profit from Clearmind Medicine as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Clearmind Medicine occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CMND, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CMND, twice per month. The most recent reporting period available is June, 30 2025.